BlackRock’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-34,714
Closed -$25.3K 5494
2023
Q4
$25.3K Hold
34,714
﹤0.01% 5057
2023
Q3
$38.9K Hold
34,714
﹤0.01% 5045
2023
Q2
$46.9K Hold
34,714
﹤0.01% 5076
2023
Q1
$36.8K Hold
34,714
﹤0.01% 5169
2022
Q4
$81.6K Hold
34,714
﹤0.01% 5103
2022
Q3
$149K Buy
34,714
+4
+0% +$22 ﹤0.01% 5052
2022
Q2
$141K Sell
34,710
-2
-0% -$11 ﹤0.01% 5131
2022
Q1
$299K Hold
34,712
﹤0.01% 5018
2021
Q4
$396K Hold
34,712
﹤0.01% 4940
2021
Q3
$607K Hold
34,712
﹤0.01% 4703
2021
Q2
$644K Sell
34,712
-8,708
-20% -$166K ﹤0.01% 4629
2021
Q1
$1.08M Buy
43,420
+43,393
+160,715% +$1.3M ﹤0.01% 4478
2020
Q4
$1K Hold
27
﹤0.01% 5041
2020
Q3
$1K Hold
27
﹤0.01% 5032
2020
Q2
$1K Hold
27
﹤0.01% 4993
2020
Q1
$1K Hold
27
﹤0.01% 4948
2019
Q4
$4K Hold
27
﹤0.01% 4829
2019
Q3
$10K Hold
27
﹤0.01% 4724
2019
Q2
$14K Hold
27
﹤0.01% 4732
2019
Q1
$31K Hold
27
﹤0.01% 4545
2018
Q4
$30K Hold
27
﹤0.01% 4544
2018
Q3
$40K Hold
27
﹤0.01% 4573
2018
Q2
$34K Sell
27
-4
-13% -$21.9K ﹤0.01% 4607
2018
Q1
$307K Hold
31
﹤0.01% 4122
2017
Q4
$446K Hold
31
﹤0.01% 4070
2017
Q3
$835K Hold
31
﹤0.01% 3961
2017
Q2
$1.58M Sell
31
-73
-70% -$3.99M ﹤0.01% 3744
2017
Q1
$7.92M Buy
+104
New +$8.4M ﹤0.01% 3215
2016
Q4
Hold
0
3402
2016
Q3
Hold
0
3345
2016
Q2
Hold
0
3401
2016
Q1
Hold
0
3056
2015
Q4
Hold
0
3184
2015
Q3
Hold
0
2975
2015
Q2
Hold
0
2754

Other funds holding NVIV

BlackRock's NVIV Position: Q1 2024 in Review

BlackRock sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2024, closing a stake of 34,714 shares — an estimated $25.3K sold.

BlackRock first reported a position in NVIV in Q1 2017 and held it in 28 quarters. The position peaked at $7.92M in Q1 2017. 4 funds tracked by Wall St. Rank hold NVIV as of Q1 2024.

  • BlackRock reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2024 after selling out during the quarter.
  • BlackRock sold 34,714 InVivo Therapeutics Holdings Corp shares in Q1 2024, an estimated $25.3K.
  • BlackRock first reported a position in InVivo Therapeutics Holdings Corp in Q1 2017 and held it in 28 quarters.
  • BlackRock's InVivo Therapeutics Holdings Corp position peaked at $7.92M in Q1 2017.
  • 4 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2024.

Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.